A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia

被引：0
|
作者：
Dahir, Kathryn [1 ]
Dunn, Derek [2 ]
Hasan, Jawad [2 ]
Shannon, Amy [2 ]
Pan, Wei-Jian [2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Alexion, AstraZeneca Rare Dis, Boston, MA USA
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2023年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SUN-492
引用
收藏
页码：374 / 374
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics, pharmacodynamics, and tolerability of JY09 in healthy Chinese subjects: A titrating, dose-escalating study
    Yang, Guangyu
    Cao, Bei
    Yang, Yuanxun
    Geng, Yan
    Lin, Hui
    Jiang, Junyi
    Zhao, Yu
    Weng, Zuyi
    Zhang, Chen
    Bai, Yi
    Li, Juan
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (11) : 608 - 616
  • [22] An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
    Simon, Marc A.
    Hanrott, Kate
    Budd, David C.
    Torres, Fernando
    Gruenig, Ekkehard
    Escribano-Subias, Pilar
    Meseguer, Manuel L.
    Halank, Michael
    Opitz, Christian
    Hall, David A.
    Hewens, Deborah
    Powley, William M.
    Siederer, Sarah
    Bayliffe, Andrew
    Lazaar, Aili L.
    Cahn, Anthony
    Rosenkranz, Stephan
    PULMONARY CIRCULATION, 2022, 12 (01)
  • [23] Safety of Ornithine Phenylacetate in Cirrhotic Decompensated Patients An Open-label, Dose-escalating, Single-cohort Study
    Ventura-Cots, Meritxell
    Arranz, Jose A.
    Simon-Talero, Macarena
    Torrens, Maria
    Blanco, Albert
    Riudor, Encarnacio
    Fuentes, Inma
    Sune, Pilar
    Soriano, German
    Cordoba, Juan
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2013, 47 (10) : 881 - 887
  • [24] Dose-escalating study to investigate safety, tolerability, and pharmacokinetics of Lonicera japonica extract in healthy volunteers
    Cho, Joo-Youn
    Kim, JaeWoo
    Lim, Kyoung Soo
    Kim, Jung-Ryul
    Kim, Bo-Hyung
    Jeon, Ji-Young
    Tae, Yu Mi
    Yu, Kyung-Sang
    Jang, In-Jin
    Shin, Sang-Goo
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 199 - 199
  • [25] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Beckermann, Kathryn E.
    Patnaik, Amita
    Winer, Ira
    Tan, Winston
    Bashir, Babar
    Kyriakopoulos, Christos E.
    Sweis, Randy F.
    Chamberlain, Marc
    Rini, Brian I.
    INVESTIGATIONAL NEW DRUGS, 2024, 42 (02) : 179 - 184
  • [26] Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study
    Khoo, Saye H.
    Fitzgerald, Richard
    Fletcher, Thomas
    Ewings, Sean
    Jaki, Thomas
    Lyon, Rebecca
    Downs, Nichola
    Walker, Lauren
    Tansley-Hancock, Olana
    Greenhalf, William
    Woods, Christie
    Reynolds, Helen
    Marwood, Ellice
    Mozgunov, Pavel
    Adams, Emily
    Bullock, Katie
    Holman, Wayne
    Bula, Marcin D.
    Gibney, Jennifer L.
    Saunders, Geoffrey
    Corkhill, Andrea
    Hale, Colin
    Thorne, Kerensa
    Chiong, Justin
    Condie, Susannah
    Pertinez, Henry
    Painter, Wendy
    Wrixon, Emma
    Johnson, Lucy
    Yeats, Sara
    Mallard, Kim
    Radford, Mike
    Fines, Keira
    Shaw, Victoria
    Owen, Andrew
    Lalloo, David G.
    Jacobs, Michael
    Griffiths, Gareth
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3286 - 3295
  • [27] A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma
    Kathryn E. Beckermann
    Amita Patnaik
    Ira Winer
    Winston Tan
    Babar Bashir
    Christos E. Kyriakopoulos
    Randy F. Sweis
    Marc Chamberlain
    Brian I. Rini
    Investigational New Drugs, 2024, 42 : 179 - 184
  • [28] Dose-escalating study to investigate safety, tolerability, and pharmacokinetics of Lonicera japonica extract in healthy volunteers.
    Kim, JW
    Lim, KS
    Kim, JR
    Kim, BH
    Jeon, JY
    Chung, OH
    Tae, YM
    Cho, JY
    Yu, KS
    Shin, SG
    Jang, IJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P58 - P58
  • [29] An Open-Label, Dose-Escalating Phase I Study of Elsamitrucin (SPI 28090) in Treatment of Malignant Solid Tumors in Dogs
    Fiocchi, S. C.
    Selting, K. A.
    Rosenberg, M. P.
    Kolli, P.
    Lenaz, G.
    Henry, C.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2011, 25 (04) : 897 - 902
  • [30] A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults with ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE): An Interim Analysis
    Sabbagh, Yves
    Shenouda, Magdy
    Taubel, Jorg
    Lebwohl, Mark
    Gunter, Kurt
    JOURNAL OF BONE AND MINERAL RESEARCH, 2023, 38 : 72 - 72
12345